Harrigan PR - Search Results

1

Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.

Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, James I, Heera J, Valdez H, Harrigan PR. Thielen A, et al. Among authors: harrigan pr. Antivir Ther. 2011;16(3):319-28. doi: 10.3851/IMP1769. Antivir Ther. 2011. PMID: 21555814

2

Predicting HIV coreceptor usage on the basis of genetic and clinical covariates.

Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Büch J, Däumer M, Kaiser R, Lengauer T, Harrigan PR. Sing T, et al. Among authors: harrigan pr. Antivir Ther. 2007;12(7):1097-106. Antivir Ther. 2007. PMID: 18018768

3

Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120.

Thielen A, Sichtig N, Kaiser R, Lam J, Harrigan PR, Lengauer T. Thielen A, et al. Among authors: harrigan pr. J Infect Dis. 2010 Nov 1;202(9):1435-43. doi: 10.1086/656600. J Infect Dis. 2010. PMID: 20874088

4

Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage.

Sander O, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS. Sander O, et al. Among authors: harrigan pr. PLoS Comput Biol. 2007 Mar 30;3(3):e58. doi: 10.1371/journal.pcbi.0030058. Epub 2007 Feb 8. PLoS Comput Biol. 2007. PMID: 17397254 Free PMC article.

5

HIV coreceptor phenotyping in the clinical setting.

Low AJ, Swenson LC, Harrigan PR. Low AJ, et al. Among authors: harrigan pr. AIDS Rev. 2008 Jul-Sep;10(3):143-51. AIDS Rev. 2008. PMID: 18820716 Review.

6

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.

McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. McGovern RA, et al. Among authors: harrigan pr. AIDS. 2010 Oct 23;24(16):2517-25. doi: 10.1097/QAD.0b013e32833e6cfb. AIDS. 2010. PMID: 20736814

7

Genotypic inference of HIV-1 tropism using population-based sequencing of V3.

McGovern RA, Harrigan PR, Swenson LC. McGovern RA, et al. Among authors: harrigan pr. J Vis Exp. 2010 Dec 27;(46):2531. doi: 10.3791/2531. J Vis Exp. 2010. PMID: 21248683 Free PMC article.

8

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. Swenson LC, et al. Among authors: harrigan pr. J Infect Dis. 2011 Jan 15;203(2):237-45. doi: 10.1093/infdis/jiq030. J Infect Dis. 2011. PMID: 21288824 Free PMC article.

9

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR. Swenson LC, et al. Among authors: harrigan pr. Clin Infect Dis. 2011 Oct;53(7):732-42. doi: 10.1093/cid/cir493. Clin Infect Dis. 2011. PMID: 21890778 Clinical Trial.

10

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. McGovern RA, et al. Among authors: harrigan pr. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf. J Acquir Immune Defic Syndr. 2012. PMID: 23095934 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters